Role of the cannabinoid signaling in the brain orexin- and ghrelin-induced visceral antinociception in conscious rats

We hypothesized that the cannabinoid (CB) system may mediate the brain orexin- or ghrelin-induced visceral antinociception. Intraperitoneal injection of either CB1/2 agonist, WIN 55212 or O-Arachidonoyl ethanolamine increased the threshold volume of colonic distension-induced abdominal withdrawal re...

Full description

Saved in:
Bibliographic Details
Main Authors: Toshikatsu Okumura (Author), Tsukasa Nozu (Author), Shima Kumei (Author), Masumi Ohhira (Author)
Format: Book
Published: Elsevier, 2018-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We hypothesized that the cannabinoid (CB) system may mediate the brain orexin- or ghrelin-induced visceral antinociception. Intraperitoneal injection of either CB1/2 agonist, WIN 55212 or O-Arachidonoyl ethanolamine increased the threshold volume of colonic distension-induced abdominal withdrawal reflex in rats, suggesting CB could induce visceral antinociception. Pretreatment with either the CB1 or CB2 antagonist potently blocked the centrally injected orexin-A-induced antinociceptive action against colonic distension while CB2 but not CB1 antagonist blocked the brain ghrelin-induced visceral antinociception. These results suggest that the cannabinoid signaling may be involved in the central orexin- or ghrelin-induced antinociceptive action in a different mechanistic manner. Keywords: Cannabinoid, Neuropeptide, Visceral sensation
Item Description:1347-8613
10.1016/j.jphs.2018.06.001